These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 33310034)

  • 21. Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.
    Kim K; Ryu D; Dongiovanni P; Ozcan L; Nayak S; Ueberheide B; Valenti L; Auwerx J; Pajvani UB
    Gastroenterology; 2017 Dec; 153(6):1568-1580.e10. PubMed ID: 28859855
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dihydromyricetin ameliorates hepatic steatosis and insulin resistance via AMPK/PGC-1α and PPARα-mediated autophagy pathway.
    Yang Y; Qiu W; Xiao J; Sun J; Ren X; Jiang L
    J Transl Med; 2024 Mar; 22(1):309. PubMed ID: 38532480
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short-term strength training reduces gluconeogenesis and NAFLD in obese mice.
    Pereira RM; Rodrigues KCDC; Anaruma CP; Sant'Ana MR; de Campos TDP; Gaspar RS; Canciglieri RDS; de Melo DG; Mekary RA; da Silva ASR; Cintra DE; Ropelle ER; Pauli JR; de Moura LP
    J Endocrinol; 2019 Apr; 241(1):59-70. PubMed ID: 30878016
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blockade of interleukin 6 signalling ameliorates systemic insulin resistance through upregulation of glucose uptake in skeletal muscle and improves hepatic steatosis in high-fat diet fed mice.
    Yamaguchi K; Nishimura T; Ishiba H; Seko Y; Okajima A; Fujii H; Tochiki N; Umemura A; Moriguchi M; Sumida Y; Mitsuyoshi H; Yasui K; Minami M; Okanoue T; Itoh Y
    Liver Int; 2015 Feb; 35(2):550-61. PubMed ID: 25066281
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Maternal exercise conveys protection against NAFLD in the offspring via hepatic metabolic programming.
    Bae-Gartz I; Kasper P; Großmann N; Breuer S; Janoschek R; Kretschmer T; Appel S; Schmitz L; Vohlen C; Quaas A; Schweiger MR; Grimm C; Fischer A; Ferrari N; Graf C; Frese CK; Lang S; Demir M; Schramm C; Fink G; Goeser T; Dötsch J; Hucklenbruch-Rother E
    Sci Rep; 2020 Sep; 10(1):15424. PubMed ID: 32963289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peroxisome proliferator-activated receptor-alpha activation and dipeptidyl peptidase-4 inhibition target dysbiosis to treat fatty liver in obese mice.
    Silva-Veiga FM; Miranda CS; Vasques-Monteiro IML; Souza-Tavares H; Martins FF; Daleprane JB; Souza-Mello V
    World J Gastroenterol; 2022 May; 28(17):1814-1829. PubMed ID: 35633911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway.
    Zhu X; Bian H; Wang L; Sun X; Xu X; Yan H; Xia M; Chang X; Lu Y; Li Y; Xia P; Li X; Gao X
    Free Radic Biol Med; 2019 Sep; 141():192-204. PubMed ID: 31226399
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic role of ursolic acid on ameliorating hepatic steatosis and improving metabolic disorders in high-fat diet-induced non-alcoholic fatty liver disease rats.
    Li S; Liao X; Meng F; Wang Y; Sun Z; Guo F; Li X; Meng M; Li Y; Sun C
    PLoS One; 2014; 9(1):e86724. PubMed ID: 24489777
    [TBL] [Abstract][Full Text] [Related]  

  • 29. N-3 long-chain PUFA supplementation prevents high fat diet induced mouse liver steatosis and inflammation in relation to PPAR-α upregulation and NF-κB DNA binding abrogation.
    Tapia G; Valenzuela R; Espinosa A; Romanque P; Dossi C; Gonzalez-Mañán D; Videla LA; D'Espessailles A
    Mol Nutr Food Res; 2014 Jun; 58(6):1333-41. PubMed ID: 24436018
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adiponectin homolog novel osmotin protects obesity/diabetes-induced NAFLD by upregulating AdipoRs/PPARα signaling in ob/ob and db/db transgenic mouse models.
    Ahmad A; Ali T; Kim MW; Khan A; Jo MH; Rehman SU; Khan MS; Abid NB; Khan M; Ullah R; Jo MG; Kim MO
    Metabolism; 2019 Jan; 90():31-43. PubMed ID: 30473057
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-altitude chronic hypoxia ameliorates obesity-induced non-alcoholic fatty liver disease in mice by regulating mitochondrial and AMPK signaling.
    Song K; Zhang Y; Ga Q; Bai Z; Ge RL
    Life Sci; 2020 Jul; 252():117633. PubMed ID: 32289432
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Salidroside inhibits insulin resistance and hepatic steatosis by downregulating miR-21 and subsequent activation of AMPK and upregulation of PPARα in the liver and muscles of high fat diet-fed rats.
    Almohawes ZN; El-Kott A; Morsy K; Shati AA; El-Kenawy AE; Khalifa HS; Elsaid FG; Abd-Lateif AM; Abu-Zaiton A; Ebealy ER; Abdel-Daim MM; Ghanem RA; Abd-Ella EM
    Arch Physiol Biochem; 2024 Jun; 130(3):257-274. PubMed ID: 35061559
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fisetin Protects Against Hepatic Steatosis Through Regulation of the Sirt1/AMPK and Fatty Acid β-Oxidation Signaling Pathway in High-Fat Diet-Induced Obese Mice.
    Liou CJ; Wei CH; Chen YL; Cheng CY; Wang CL; Huang WC
    Cell Physiol Biochem; 2018; 49(5):1870-1884. PubMed ID: 30235452
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular adaptations underlying the beneficial effects of hydroxytyrosol in the pathogenic alterations induced by a high-fat diet in mouse liver: PPAR-α and Nrf2 activation, and NF-κB down-regulation.
    Valenzuela R; Illesca P; Echeverría F; Espinosa A; Rincón-Cervera MÁ; Ortiz M; Hernandez-Rodas MC; Valenzuela A; Videla LA
    Food Funct; 2017 Apr; 8(4):1526-1537. PubMed ID: 28386616
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of AMPKα2 in the HFD-induced nonalcoholic steatohepatitis.
    Zhang X; Liu S; Zhang C; Zhang S; Yue Y; Zhang Y; Chen L; Yao Z; Niu W
    Biochim Biophys Acta Mol Basis Dis; 2020 Oct; 1866(10):165854. PubMed ID: 32502647
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice.
    Ideta T; Shirakami Y; Miyazaki T; Kochi T; Sakai H; Moriwaki H; Shimizu M
    Int J Mol Sci; 2015 Dec; 16(12):29207-18. PubMed ID: 26670228
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term subcutaneous injection of lipopolysaccharides and high-fat diet induced non-alcoholic fatty liver disease through IKKε/ NF-κB signaling.
    He Q; Zeng J; Yao K; Wang W; Wu Q; Tang R; Xia X; Zou X
    Biochem Biophys Res Commun; 2020 Nov; 532(3):362-369. PubMed ID: 32883523
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of the new thiazolidine derivative LPSF/GQ-02 on hepatic lipid metabolism pathways in non-alcoholic fatty liver disease (NAFLD).
    Araújo S; Soares E Silva A; Gomes F; Ribeiro E; Oliveira W; Oliveira A; Lima I; Lima MDC; Pitta I; Peixoto C
    Eur J Pharmacol; 2016 Oct; 788():306-314. PubMed ID: 27349145
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting arginase-II protects mice from high-fat-diet-induced hepatic steatosis through suppression of macrophage inflammation.
    Liu C; Rajapakse AG; Riedo E; Fellay B; Bernhard MC; Montani JP; Yang Z; Ming XF
    Sci Rep; 2016 Feb; 6():20405. PubMed ID: 26846206
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Wuzhi capsule (Schisandra Sphenanthera extract) attenuates liver steatosis and inflammation during non-alcoholic fatty liver disease development.
    Chen Z; Liu F; Zheng N; Guo M; Bao L; Zhan Y; Zhang M; Zhao Y; Guo W; Ding G
    Biomed Pharmacother; 2019 Feb; 110():285-293. PubMed ID: 30522014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.